Published in Biochem Pharmacol on May 01, 2003
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet (2016) 0.99
Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2013) 0.96
Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos (2008) 0.92
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS One (2012) 0.82
Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol (2012) 0.81
Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects. Br J Clin Pharmacol (2012) 0.77
Required propofol dose for anesthesia and time to emerge are affected by the use of antiepileptics: prospective cohort study. BMC Anesthesiol (2015) 0.75
Soybean greatly reduces valproic acid plasma concentrations: a food-drug interaction study. Sci Rep (2014) 0.75
Requirements for generic anti-epileptic medicines: a regulatory perspective. J Neurol (2009) 0.75
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics (2005) 2.98
Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol (2007) 2.68
Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos (2002) 1.70
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res (2003) 1.14
Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat. J Neurotrauma (2006) 1.10
Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol (2005) 1.05
Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy (2008) 0.98
Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury. Oxid Med Cell Longev (2010) 0.97
Pioglitazone: effect on CYP3A4 activity. J Clin Pharmacol (2002) 0.92
Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol (2006) 0.91
A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med (2008) 0.90
Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol (2006) 0.90
The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. Biochim Biophys Acta (2002) 0.88
Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet (2014) 0.88
Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. Arch Biochem Biophys (2003) 0.88
A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat. J Neurotrauma (2012) 0.87
Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. Behav Brain Res (2011) 0.87
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol (2002) 0.86
Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos (2003) 0.86
Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia (2007) 0.86
The red blood cell participates in regulation of the circulation by producing and releasing epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat (2011) 0.85
Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos (2006) 0.85
Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP). Pharmacol Rep (2010) 0.84
N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther (2004) 0.84
Is ethnicity associated with morphine's side effects in children? Morphine pharmacokinetics, analgesic response, and side effects in children having tonsillectomy. Paediatr Anaesth (2012) 0.84
Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos (2002) 0.83
Evidence for multiple glucuronide transporters in rat liver microsomes. Biochem Pharmacol (2004) 0.82
Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. Paediatr Anaesth (2010) 0.82
Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother (2007) 0.81
Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1. Biochem J (2004) 0.81
Voltage-dependent block of N-methyl-D-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of L-(+)-beta-hydroxybutyrate. Epilepsia (2003) 0.81
Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anesth Analg (2007) 0.81
Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily. Biochem Pharmacol (2003) 0.80
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet (2002) 0.79
A novel method for the immunoquantification of UDP-glucuronosyltransferases in human tissue. Drug Metab Dispos (2011) 0.79
Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 0.79
Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family. Biochem J (2006) 0.79
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). Clin Pharmacokinet (2014) 0.78
Digoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure: effect of mild-moderate renal impairment. J Clin Epidemiol (2003) 0.78
Histone 2A stimulates glucose-6-phosphatase activity by permeabilization of liver microsomes. Biochem J (2002) 0.78
Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med (2002) 0.77
Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin). Arch Toxicol (2006) 0.77
Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration. Antimicrob Agents Chemother (2009) 0.77
MRP1-transfected cells do not show increased resistance against oxidative stress. Free Radic Res (2003) 0.77
Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model. J Neurotrauma (2014) 0.77
Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression. Brain Res Mol Brain Res (2005) 0.77
Characterization of catechol glucuronidation in rat liver. Drug Metab Dispos (2002) 0.77
Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol (2007) 0.77
Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. J Clin Pharmacol (2010) 0.75
Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide. Ther Clin Risk Manag (2009) 0.75
Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action. Neurology (2007) 0.75
Glucuronidation of HMR1098 in human microsomes: evidence for the involvement of UGT1A1 in the formation of S-glucuronides. Drug Metab Dispos (2003) 0.75
Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon. Anticancer Res (2006) 0.75
Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by beta-naphthoflavone in comparison with humans. Biochem Pharmacol (2002) 0.75
Identification of the rabbit liver UDP-glucuronosyltransferase catalyzing the glucuronidation of 4-ethoxyphenylurea (dulcin). Drug Metab Dispos (2004) 0.75
Application of high-performance liquid chromatography-electrospray ionization-mass spectrometry to measure microsomal membrane transport of glucuronides. Anal Biochem (2005) 0.75
Assessment of catechol induction and glucuronidation in rat liver microsomes. Drug Metab Dispos (2004) 0.75
Ethanol-dependent induction of bilirubin UDP-glucuronosyl-transferase in rat liver is mediated by Kupffer cells. Life Sci (2002) 0.75